Monitoring mAb proteoforms in mouse plasma using an automated immunocapture combined with top-down and middle-down mass spectrometry.

Monoclonal antibodies (mAbs) have established themselves as the leading biopharmaceutical therapeutic modality. Once the developability of a mAb drug candidate has been assessed, an important step is to check its in vivo stability through pharmacokinetics (PK) studies. The gold standard is ligand-binding assay (LBA) and liquid chromatography-mass spectrometry (LC-MS) performed at the peptide level (bottom-up approach).

[Alzheimer's disease and the organization of visits to cultural sites].

In the framework of a policy to open up cultural sites within the city to the specific disability of Alzheimer's disease, the Resource and Research Memory Centre at Nice general hospital in partnership with Nice's city hall, has developed a cultural programme. The aim of this project is to assess the therapeutic aspects of this programme and notably the perception of the disease by the family carers.